Clinical Criteria

Heart Rate
0
Revised Geneva Score (0–25)
Risk Category
🟢 Low Probability (0–3)

PE prevalence ~8%
Sensitivity ~96% (D-dimer strategy)
Specificity ~49% (low-risk threshold)
Recommended Workup High-sensitivity D-dimer. If negative, PE excluded (NPV >99%). If positive, proceed to CTPA.
⚕️ Clinical Disclaimer: This calculator is for educational purposes only. The Revised Geneva Score guides, but does not replace, clinical judgment. In hemodynamically unstable patients with suspected massive PE, bedside echocardiography should guide immediate management. The score is not validated for pregnant patients.

How to Use the Revised Geneva Score Calculator

The Revised Geneva Score calculator applies the validated 8-criterion scoring system to estimate pre-test probability for pulmonary embolism using only objective clinical variables. Follow these steps:

  1. Check each criterion that applies — Evaluate all 8 criteria based on the patient's current presentation. The highest-weighted item is pain on deep venous palpation with unilateral edema (+4 points).
  2. Select the correct heart rate range — Heart rate criteria are mutually exclusive: select <75 bpm (0 points), 75–94 bpm (+3 points), or ≥95 bpm (+5 points). Only one can apply.
  3. Note the total score and risk tier — The calculator updates in real time. Scores 0–3 are low probability, 4–10 intermediate, and ≥11 high probability.
  4. Follow the recommended workup pathway — Low probability: D-dimer; if negative, PE excluded. Intermediate: D-dimer preferred; if positive, CTPA. High probability: proceed directly to CTPA without D-dimer.
  5. Consider age-adjusted D-dimer cutoffs in older patients — For patients over 50, age-adjusted cutoffs (age × 10 µg/L) improve specificity without compromising sensitivity.

About the Revised Geneva Score

The Revised Geneva Score is a clinical prediction rule for estimating pre-test probability of pulmonary embolism, published by Le Gal et al. in 2006 (Annals of Internal Medicine). It is the primary alternative to the Wells PE score and was designed to address a fundamental limitation of the Wells system: the inclusion of a subjective criterion ("PE is the most likely diagnosis") worth 3 points, which introduces interobserver variability.

The Geneva score uses only objective, measurable variables — patient age, documented history, recent procedures, vital signs, and physical examination findings. This makes it particularly suitable for research settings, protocol-driven clinical pathways, and environments where less experienced clinicians make initial triage decisions.

The original Geneva score (Wicki et al., 2001) used 7 variables including arterial blood gas values, making it impractical for bedside use. The 2006 revision simplified the criteria to bedside-obtainable variables while maintaining equivalent diagnostic performance. A further simplified version (the Simplified Revised Geneva Score) assigns 1 point to each criterion, but the standard revised version retains higher discriminative power with weighted scoring.

Risk Tiers & Clinical Decision Pathways

ScoreCategoryPE PrevalenceStrategy
0–3 Low ~8% D-dimer; if negative, PE excluded (NPV >99%)
4–10 Intermediate ~29% D-dimer preferred; if positive, proceed to CTPA
≥11 High ~74% CTPA directly (D-dimer unreliable at this pre-test probability)
~8% Low risk PE prevalence
~29% Intermediate prevalence
~74% High risk prevalence
>99% NPV (low + neg D-dimer)

D-dimer and CT-PA Decision Guidance

Low probability (0–3): Order a high-sensitivity D-dimer. A negative result effectively excludes PE with NPV exceeding 99%. No further imaging is required. If positive, proceed to CT pulmonary angiography (CTPA).

Intermediate probability (4–10): D-dimer is the preferred first-line test. If negative, PE can be safely excluded. If positive or if D-dimer is unavailable, proceed directly to CTPA. Consider age-adjusted D-dimer cutoffs (age × 10 µg/L for patients over 50) to improve specificity without sacrificing sensitivity.

High probability (≥11): Proceed directly to CTPA. Do not rely on D-dimer to exclude PE in high-probability patients — a negative D-dimer does not safely rule out PE when pre-test probability exceeds 60%. Consider empiric anticoagulation if CTPA will be significantly delayed.

Revised Geneva Score vs Wells PE Score

The Revised Geneva Score and the Wells PE Score are the two most widely validated pre-test probability tools for pulmonary embolism. Here is a direct comparison:

FeatureRevised Geneva ScoreWells PE Score
Subjective criterionNo — all variables are objectiveYes — "PE most likely diagnosis" (+3 pts)
Variables8 criteria (age, HR, surgery/fracture, cancer, leg pain, palpation/edema, hemoptysis, prior VTE)7 criteria
Score range0–250–12.5
Interobserver variabilityLower — all items are objective measurementsModerate (κ ≈ 0.5–0.7 for subjective item)
AUC (validation)~0.72–0.78~0.72–0.78
Stratification3 tiers only3-tier and 2-tier (dichotomized) options
Geographic preferenceMore common in EuropeDominant in North America
Guideline endorsementESC, NICEACCP, BTS, ESC

Neither score is clinically superior. Head-to-head validation studies show equivalent diagnostic performance. The Geneva score tends to classify fewer patients into the high-probability tier due to its purely objective criteria, which may result in more patients undergoing D-dimer testing rather than proceeding directly to CTPA.

Sensitivity & Specificity

Diagnostic performance data from the original Le Gal et al. validation cohort (2006, n=965) and subsequent meta-analyses:

TierSensitivitySpecificity3-month VTE Rate (if PE excluded by algorithm)
Low (0–3)~96% (Geneva + D-dimer)~49%<1%
Intermediate (4–10)<2% (with negative D-dimer)
High (≥11)>95% (CTPA)>95% (CTPA)N/A (CTPA indicated)

Limitations & Considerations

The Revised Geneva Score has important limitations. While eliminating subjective assessment improves reproducibility, several criteria still require clinical interpretation. "Unilateral lower limb pain" and "pain on deep venous palpation with unilateral edema" require physical examination that can vary between examiners, though less so than the Wells "PE most likely diagnosis" criterion.

The score is not validated for pregnant patients, in whom PE risk is substantially elevated and D-dimer is physiologically elevated throughout pregnancy. The British Thoracic Society recommends V/Q scintigraphy as the preferred initial imaging test in pregnancy.

In hemodynamically unstable patients with suspected massive PE, bedside echocardiography and clinical gestalt should guide immediate management rather than formal scoring. The Geneva score is designed for stable patients in whom a structured diagnostic algorithm can be safely completed.

The score does not incorporate age-adjusted D-dimer cutoffs directly. When applying D-dimer testing in patients over 50, clinicians should consider using age-adjusted thresholds (age × 10 µg/L) to reduce false-positive rates without compromising sensitivity.

The score does not risk-stratify PE after diagnosis. For post-diagnosis severity assessment, use the PESI or sPESI score to guide decisions about outpatient treatment, ICU admission, or thrombolysis candidacy.

References

Le Gal G, Righini M, Roy PM, et al. Prediction of pulmonary embolism in the emergency department: the revised Geneva score. Ann Intern Med. 2006;144(3):165–171.

Klok FA, Mos IC, Nijkeuter M, et al. Simplification of the revised Geneva score for assessing clinical probability of pulmonary embolism. Arch Intern Med. 2008;168(19):2131–2136.

Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2020;41(4):543–603.

Wicki J, Perneger TV, Junod AF, et al. Assessing clinical probability of pulmonary embolism in the emergency ward: a simple score. Arch Intern Med. 2001;161(1):92–97.

Wells PS, Anderson DR, Rodger M, et al. Derivation of a simple clinical model to categorize patients probability of pulmonary embolism. Thromb Haemost. 1998;83:416–420.